ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024
ENDRA Life Sciences (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has rescheduled its second quarter conference call to August 22, 2024, at 4:30 p.m. Eastern time. The call was previously set for August 14, 2024. ENDRA will file its quarterly report on form 10-Q with the SEC as planned and issue a press release summarizing financial and operating results for Q2 2024 on the day of the call.
Participants can pre-register for the call using a provided link to receive a unique PIN for immediate access. Those unable to pre-register can dial (844) 868-8846 (U.S.) or (412) 317-5465 (International). A webcast will be available on ENDRA's Investor Relations page. A telephone replay will be accessible until August 29, 2024, and a webcast replay will be available shortly after the call.
ENDRA Life Sciences (NASDAQ: NDRA), un pioniere della tecnologia Thermo Acoustic Enhanced UltraSound (TAEUS®), ha riprogrammato la sua call di conferenza del secondo trimestre per il 22 agosto 2024 alle 16:30 ora orientale. La chiamata era precedentemente prevista per il 14 agosto 2024. ENDRA presenterà il proprio rapporto trimestrale in forma 10-Q alla SEC come previsto e emetterà un comunicato stampa che riassume i risultati finanziari e operativi per il secondo trimestre 2024 il giorno della chiamata.
I partecipanti possono preregistrarsi per la chiamata utilizzando un link fornito per ricevere un PIN unico per l'accesso immediato. Coloro che non possono preregistrarsi possono comporre il numero (844) 868-8846 (USA) o (412) 317-5465 (internazionale). Un webcast sarà disponibile sulla pagina delle Relazioni con gli Investitori di ENDRA. Una registrazione telefonica sarà accessibile fino al 29 agosto 2024 e una registrazione del webcast sarà disponibile poco dopo la chiamata.
ENDRA Life Sciences (NASDAQ: NDRA), pionero en la tecnología Thermo Acoustic Enhanced UltraSound (TAEUS®), ha reprogramado su llamada de conferencia del segundo trimestre para el 22 de agosto de 2024 a las 4:30 p.m. hora del Este. La llamada estaba previamente programada para el 14 de agosto de 2024. ENDRA presentará su informe trimestral en el formulario 10-Q ante la SEC como estaba planeado y emitirá un comunicado de prensa que resume los resultados financieros y operativos para el Q2 2024 el día de la llamada.
Los participantes pueden preregistrarse para la llamada utilizando un enlace proporcionado para recibir un PIN único para acceso inmediato. Aquellos que no puedan preregistrarse pueden marcar (844) 868-8846 (EE. UU.) o (412) 317-5465 (internacional). Un webcast estará disponible en la página de Relaciones con Inversores de ENDRA. Una grabación telefónica estará accesible hasta el 29 de agosto de 2024, y una grabación del webcast estará disponible poco después de la llamada.
ENDRA Life Sciences (NASDAQ: NDRA), Thermo Acoustic Enhanced UltraSound (TAEUS®)의 선구자로서 두 번째 분기 컨퍼런스 콜을 2024년 8월 22일 오후 4시 30분(동부 표준시)로 변경했습니다. 이 콜은 원래 2024년 8월 14일로 예정되어 있었습니다. ENDRA는 예정대로 SEC에 10-Q 양식으로 분기 보고서를 제출하고, 콜 당일에 Q2 2024에 대한 재무 및 운영 결과를 요약한 보도 자료를 발표할 것입니다.
참가자는 제공된 링크를 통해 미리 등록하여 즉시 접근할 수 있는 고유한 PIN을 받을 수 있습니다. 미리 등록할 수 없는 경우 (844) 868-8846 (미국) 또는 (412) 317-5465 (국제전용)로 전화할 수 있습니다. ENDRA의 투자자 관계 페이지에서 웹캐스트가 제공됩니다. 전화 재생은 2024년 8월 29일까지 이용할 수 있으며, 콜 직후 웹캐스트 재생이 제공될 것입니다.
ENDRA Life Sciences (NASDAQ: NDRA), un pionnier de la technologie Thermo Acoustic Enhanced UltraSound (TAEUS®), a reprogrammé sa conférence téléphonique du deuxième trimestre au 22 août 2024 à 16h30 heure de l'Est. L'appel était initialement prévu pour le 14 août 2024. ENDRA déposera son rapport trimestriel sous le formulaire 10-Q auprès de la SEC comme prévu et publiera un communiqué de presse résumant les résultats financiers et opérationnels pour le T2 2024 le jour de l'appel.
Les participants peuvent s'inscrire à l'avance pour l'appel en utilisant un lien fourni afin de recevoir un PIN unique pour un accès immédiat. Ceux qui ne peuvent pas s'inscrire à l'avance peuvent composer le (844) 868-8846 (États-Unis) ou le (412) 317-5465 (international). Un webinaire sera disponible sur la page des relations avec les investisseurs d'ENDRA. Une rediffusion téléphonique sera accessible jusqu'au 29 août 2024, et une rediffusion du webinaire sera disponible peu après l'appel.
ENDRA Life Sciences (NASDAQ: NDRA), ein Pionier der Thermo Acoustic Enhanced UltraSound (TAEUS®), hat seinen Konferenzanruf für das zweite Quartal auf den 22. August 2024 um 16:30 Uhr Eastern Time verschoben. Der Anruf war zuvor für den 14. August 2024 angesetzt. ENDRA wird wie geplant seinen Quartalsbericht im Formular 10-Q bei der SEC einreichen und am Tag des Anrufs eine Pressemitteilung veröffentlichen, die die finanziellen und betrieblichen Ergebnisse für Q2 2024 zusammenfasst.
Teilnehmer können sich über einen bereitgestellten Link im Voraus registrieren, um eine einzigartige PIN für den sofortigen Zugang zu erhalten. Wer sich nicht im Voraus registrieren kann, kann (844) 868-8846 (USA) oder (412) 317-5465 (international) wählen. Ein Webcast wird auf der Investor-Relations-Seite von ENDRA verfügbar sein. Eine Telefonwiederholung wird bis zum 29. August 2024 zugänglich sein, und eine Webcast-Wiederholung wird kurz nach dem Anruf verfügbar sein.
- None.
- None.
The Company will file its quarterly report on form 10-Q with the SEC as regularly scheduled in the coming days. A press release summarizing its financial and operating results for the second quarter ending on June 30, 2024, will be issued on the day of the call.
Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the start of the call. Those unable to pre-register may participate by dialing (844) 868-8846 (
A telephone replay will be available until August 29, 2024 by dialing (877) 344-7529 (
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology that characterizes tissue similar to an MRI, but at 1/40th the cost and at the point of patient care. TAEUS® is designed to work in concert with the more than 700,000 ultrasound systems in use globally today. TAEUS® is initially focused on the non-invasive assessment of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including non-invasive visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813212894/en/
Company:
Richard Jacroux
Chief Financial Officer
investors@endrainc.com
www.endrainc.com
Investor Relations:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com
Source: ENDRA Life Sciences Inc.
FAQ
When is ENDRA Life Sciences (NDRA) holding its Q2 2024 conference call?
How can investors participate in ENDRA's (NDRA) Q2 2024 conference call?
Will ENDRA Life Sciences (NDRA) provide a replay of the Q2 2024 conference call?
What is ENDRA Life Sciences' (NDRA) main technology focus?
